Marker Therapeutics

Marker Therapeutics has rapidly gained recognition for its cutting-edge research and development in the field of cancer immunotherapy. The company’s establishment revolves around the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood and solid tumor cancers. With a dedicated team of talented and passionate professionals, all experts in the field of cancer immunotherapy, Marker Therapeutics is on a mission to deliver effective treatments to patients who currently have few or no therapeutics options.

Marker Therapeutics works to leverage its novel MultiTAA technology – which uses non-genetically engineered T cells designed to recognize and kill multiple tumor targets – to develop more precise and safer therapies capable of resulting in broad, potent and durable anti-cancer activity.

Marker Therapeutics started their non-dilutive funding journey with FreeMind Group in 2020, to secure non-dilutive funding for their research and development in the cancer immunotherapy sector.

As Marker Therapeutics continues to push the boundaries of scientific discovery, the future holds immense promise. With ongoing research, development initiatives, and a commitment to excellence, Marker Therapeutics is well-positioned to shape the future of healthcare.

“It is an honor to be recognized as a FreeMind Elite honoree. FreeMind has played a central role in securing competitive, non-dilutive funding to support the clinical investigation of our T cell therapies. We thank FreeMind for our existing partnership and look forward to solidify our shared commitment to novel innovative immunotherapies and improved patient outcomes.”

Marker Therapeutics FreeMind Elite Presentation at NDFS 2024